GlobeNewsWire
06 Aug 2026, 10:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Pharvaris is conducting a Phase 3 CREAATE study investigating deucrictibant for the prophylaxis and on-demand treatment of AAE-C1INH. — Phase 3 trials are the final critical step before regulatory filing, and success in an area with no approved therapies presents a high-value commercial opportunity.
+0.50There are currently no approved therapies for the prevention or treatment of AAE-C1INH attacks. — The absence of competition in this specific indication creates a high probability of market capture and pricing power if the drug is approved.
+0.40Pharvaris published a qualitative study validating patient-reported outcome (PRO) measures to inform the endpoints of the Phase 3 trial. — Aligning trial endpoints with FDA guidance and patient experience reduces regulatory risk and increases the likelihood of trial success.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company published a qualitative study that strengthens the scientific foundation and clinical trial design for its lead candidate in AAE-C1INH.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
16h ago
